Professional Documents
Culture Documents
NAME
1.1 Substance
Chlorpromazine
(INN, 1992)
1.2 Group
Psycholeptics (N05)/
Antipsychotics (N05A)
(ATC classification index [WHO] 1992])
1.3 Synonyms
Chlorpromazini hydrochloridum
Aminazine
(Martindale, 1993)
1.4 Identification numbers
1.4.1 CAS
Chlorpromazine 50-53-3
1.4.2 Other numbers
Chlorpromazine hydrochloride 69-09-0
RTECS SN8925000
1.5 Brand names, Trade names
Ampliactil
Cesalgin
Largactil
Promactil
Thorazine
Aminasine
(To be completed by each Centre using local datata)
1.6 Manufacturers, Importers
Rhone-Poulenc, Rhodia Argentina SA, Cetus
2. SUMMARY
2.3 Diagnosis
3. PHYSICO-CHEMICAL PROPERTIES
Structural formula
Molecular formula
Chlorpromazine C17H19C1N2S
Chlorpromazine (C17H19ClN2S)2,C23H16O6
embonate
Chlorpromazine C17H19C1N2S,HCl
hydrochloride
Molecular weight
Chlorpromazine 318.9
Chlorpromazine 1026.1
embonate
Chlorpromazine 355.3
hydrochloride
Chemical names
3-(2-Chlorophenothiazin-10-yl)propyldimethylamine
2-Chloro-N,N-dimethyl-10H-phenothiazine-10-propanamine
2-Chloro-10-(3-dimethylaminopropyl)phenothiazine
N-(3-dimethylaminopropyl)-3-chlorophenothiazine
3.3.1.1 Colour
3.3.1.3 Description
Chlorpromazine base
Chlorpromazine hydrochloride
(Martindale, 1993)
No data available
(Martindale, 1993)
4.1 Indications
4.1.1 Indications
4.1.2 Description
4.2.1 Adults
Oral (Hydrochloride)
25 mg to 50 mg three times a day (initial dose).
Parenteral
Intramuscular
Intravenous
25 mg to 50 mg (repeated as required).
Rectal
(Martindale, 1993).
4.2.2 Children
Oral
Parenteral
Intramuscular
Rectal
25 mg suppositories available.
1 to 5 years 40 mg
More than 5 75 mg
years
(Martindale, 1993)
4.3 Contraindications
5. ROUTES OF ENTRY
5.1 Oral
5.2 Inhalation
Not relevant.
5.3 Dermal
Not relevant.
5.4 Eye
Not relevant.
5.5 Parenteral
5.6 Other
6.4 Metabolism
Paths of metabolism of chlorpromazine include hydroxylation,
and conjugation with glucuronic acid, N-oxidation, oxidation
of a sulphur atom, and dealkylation.
7.1.1 Toxicodynamics
7.1.2 Pharmacodynamics
7.2 Toxicity
7.2.1.1 Adults
LD50
Species Oral mg/kg intraperit. intravenous
mg/kg mg/kg
No data available.
7.3 Carcinogenicity
No data available.
7.4 Teratogenicity
7.5 Mutagenicity
No data available.
7.6 Interactions
+ ++ +++ ++++
"Basic analyses"
"Dedicated analyses"
"Optional analyses"
8.3.1.2 Urine
"Basic analyses"
"Dedicated analyses"
"Optional analyses"
"Basic analyses"
"Dedicated analyses"
"Optional analyses"
8.6 References
9. CLINICAL EFFECTS
9.1 Acute Poisoning
9.1.1 Ingestion
9.1.2 Inhalation
Not relevant.
Not relevant.
Not relevant.
See 9.1.1.
9.1.6 Other
9.2.1 Ingestion
The phenothiazines have a high therapeutic index and
are remarkably safe agents. Furthermore, most
phenothiazines have a relatively flat dose-response
curve, so that they can be used over a wide range of
dosage. Side effects are extensions of the many
pharmacological actions of the drugs. The most
important are those on the CNS, cardiovascular system,
and endocrine functions. The extrapyramidal effects
are of great importance. The most dangerous effects of
the phenothiazines are those resulting from
hypersensitivity reactions, particularly blood
dyscrasias.
9.2.2 Inhalation
9.2.6 Other
9.4.1 Cardiovascular
9.4.2 Respiratory
9.4.3 Neurological
Tardive dyskinesia
9.4.4 Gastrointestinal
9.4.5 Hepatic
9.4.6.1 Renal
9.4.6.2 Other
No data available.
9.4.8 Dermatological
9.4.10 Haematological
9.4.11 Immunological
No data available.
9.4.12 Metabolic
No data available.
9.4.12.2 Fluid and electrolyte disturbances
No data available.
9.4.12.3 Others
Pregnancy
Breast-feeding
9.5 Other
No data available.
10. MANAGEMENT
Not relevant
Tardive dyskinesia
Thermal dysregulation
Seizures
10.4 Decontamination
10.5 Elimination
10.6.1 Adults
There is no antidote.
10.6.2 Children
There is no antidote.
Case 1
Case 2
Case 3
No data available.
12.3 Other
Not relevant
13. REFERENCES
Tel:
Fax:
Date
http://www.inchem.org/documents/pims/pharm/chlorpro.htm